Allogene Therapeutics Stock Earnings Reports

Allogene reported positive early clinical and financial updates. Key clinical highlights: In the ALPHA-3 first‑line consolidation trial for large B‑cell lymphoma (SemiCell) an interim futility analysis of the first 24 patients showed MRD clearance of 58.3% for SemiCell versus 16.7% for observation (41.6 percentage point absolute difference), with rapid ctDNA reductions in the treatment arm. No CRS, ICANS, or treatment‑related hospitalizations were observed in that cohort, supporting outpatient administration and broad community‑center feasibility. ALPHA‑3 is enrolling globally (now >60 sites, expanding in Asia Pacific) with an interim EFS analysis planned for mid‑2027 and primary EFS analysis in mid‑2028. ALLO‑329 (autoimmune indications) is in dose escalation (9 patients treated to date at low doses of 20M and 40M cells, with and without cyclophosphamide); investigators report early signs of activity and favorable tolerability. The next ALLO‑329 cohort is 80M cells. A more comprehensive ALLO‑329 update is expected in Q4. Financials and guidance: Q1 cash was $266.9M and a subsequent public offering raised ~$200.4M, extending the cash runway into 2029. 2026 operating cash expense guidance was increased modestly to ~$165M (from ~$150M); GAAP operating expenses to ~$225M (including ~ $35M noncash stock comp). Company priorities: complete ALPHA‑3 enrollment, progress ALLO‑329 dose escalation, provide a Q4 ALLO‑329 update, and execute toward the mid‑2027 interim EFS milestone.